Daniel Catenacci's guest appearances

Daniel Catenacci

Research To Practice | Oncology Videos

The Pipeline Show

WIN Symposium 2013

Oncology Today with Dr Neil Love

Arjun Balar

Philip A Philip

Waldenström Macroglobulinemia

Ursula Matulonis

Jeff Sharman

Hodgkin Lymphomas

Myeloproliferative Neoplasms

Ross Camidge

Aaron T Gerds

Leora Horn

Maha Hussain

Erika Hamilton

Stephen Liu

Noopur Raje

Benjamin Levy

OwlTail

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Gastroesophageal Cancers — Faculty Presentation 2: Optimal Management of HER2-Positive and FGFR2-Positive Gastroesophageal Cancers — Dr Catenacci. CME information and select publications

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Gastroesophageal Cancers — Faculty Presentation 2: Optimal Management of HER2-Positive and FGFR2-Positive Gastroesophageal Cancers — Dr Catenacci. <a href="m.researchtopractice.com/GICancers21/Gastric/Presentations" rel="nofollow" target="_blank">CME information and select publications</a>

Gastrointestinal Cancers | Daniel Catenacci, MD

Dr Daniel Catenacci from the University of Chicago Medicine and Biological Sciences discusses recently published and emerging research in the management of gastroesophageal cancers. CME information and select publications here.

Dr Daniel Catenacci from the University of Chicago Medicine and Biological Sciences discusses recently published and emerging research in the management of gastroesophageal cancers. CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodayGastric20" rel="nofollow" target="_blank">here</a>.

Management of Gastroesophageal Cancers with Dr Daniel Catenacci

Dr Daniel Catenacci talks to ecancer at the 2013 WIN Symposium in Paris about inter and intra patient tumour heterogeneity, molecularly, within the context of gastroesophageal adenocarcinoma.In the case of inter patient heterogeneity, patients all have an individual molecular profile and in cases of intra patient molecular heterogeneity, clinicians deal with the physical space the tumour occupies and progression over time.Dealing with this is heterogeneity is one the major hurdles in major molecular therapies. As more is understood about these settings it becomes a strain on the classic clinical trial design, which has lead to the implementation of PANGEA.

Dr Daniel Catenacci talks to ecancer at the 2013 WIN Symposium in Paris about inter and intra patient tumour heterogeneity, molecularly, within the context of gastroesophageal adenocarcinoma. In the case of inter patient heterogeneity, patients all have an individual molecular profile and in cases of intra patient molecular heterogeneity, clinicians deal with the physical space the tumour occupies and progression over time. Dealing with this is heterogeneity is one the major hurdles in major molecular therapies. As more is understood about these settings it becomes a strain on the classic clinical trial design, which has lead to the implementation of PANGEA.

Strategies to address inter- and intra- patient tumour heterogeneity: PANGEA: Dr Daniel Catenacci